Valuation: NOVARTIS

Market Cap 272B 243B 226B 206B 389B 26,370B 390B 2,725B 1,068B 13,444B 1,023B 1,001B 43,144B P/E 2026 *
20.1x
P/E 2027 * 16.8x
Enterprise Value 304B 272B 253B 230B 434B 29,430B 436B 3,041B 1,191B 15,004B 1,142B 1,117B 48,150B EV / Sales 2026 *
5.27x
EV / Sales 2027 * 4.91x
Free-Float
91.66%
Yield 2026 *
3.02%
Yield 2027 * 3.15%
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+3.19%+41.49%+103.56% 1,051B
+1.93%+2.11%+37.08%+65.09% 630B
+1.49%+5.19%+19.94%+85.69% 489B
+2.26%+0.90%+69.32%+40.53% 359B
+1.45%+3.50%+23.29%+41.62% 344B
+1.17%+2.37%+13.47%+33.64% 272B
+0.89%+1.08%-6.13%+9.29% 246B
+1.82%+2.94%+42.99%+52.95% 224B
+2.77%+4.44%+29.01%+98.99% 187B
Average +1.62%+2.53%+30.05%+59.04% 422.63B
Weighted average by Cap. +1.47%+2.44%+33.36%+69.01%

Financials

2026 *2027 *
Net sales 57.65B 51.49B 47.9B 43.57B 82.26B 5,579B 82.61B 576B 226B 2,845B 216B 212B 9,128B 61.33B 54.78B 50.96B 46.35B 87.51B 5,936B 87.89B 613B 240B 3,026B 230B 225B 9,711B
Net income 14.59B 13.03B 12.12B 11.02B 20.81B 1,412B 20.9B 146B 57.15B 720B 54.78B 53.58B 2,310B 16.18B 14.45B 13.44B 12.23B 23.09B 1,566B 23.19B 162B 63.4B 798B 60.76B 59.43B 2,562B
Net Debt 31.62B 28.24B 26.27B 23.89B 45.11B 3,060B 45.31B 316B 124B 1,560B 119B 116B 5,006B 28.66B 25.6B 23.81B 21.66B 40.89B 2,774B 41.07B 287B 112B 1,414B 108B 105B 4,538B
Logo NOVARTIS
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Ratings Surperformance© - NOVARTIS